Bruker Daltonics Appoints Michael Schubert as Executive Vice President and Ian Sanders as Vice President
September 01 2005 - 3:05PM
Business Wire
Bruker Daltonics Inc. today announces two promotions to further
strengthen its senior management team. Dr. Michael Schubert has
been promoted to Executive Vice President of the Bruker Daltonics
group. He retains his previous responsibilities for Bruker
Daltonics' global R&D management, as well as his function as
Managing Director (Geschaeftsfuehrer) of Bruker Daltonik GmbH,
located in Bremen and Leipzig, Germany. In addition, Dr. Schubert
now also assumes responsibility for the Company's life-science mass
spectrometry business in the Americas. Dr. Schubert joined Bruker
Daltonics in 1991, and has held several project and R&D
management positions. In 2002, he became Managing Director of
Bruker Daltonik GmbH, and in 2004 Vice President for R&D of
Bruker Daltonics. He holds a doctorate from the University of
Hamburg in physics. Ian Sanders, Ph.D., has been promoted to Vice
President for European Life Science Sales, a function that he has
previously managed as an Assistant Vice President. He also
continues in his role as Managing Director of Bruker Daltonik GmbH.
Dr. Sanders joined Bruker Daltonics in 2000 following a ten-year
career in drug discovery research for both large pharmaceutical and
venture biotechnology companies. Initially responsible for the UK
business, in 2002 his role expanded to manage life-science sales in
the UK, Scandinavia and The Netherlands. In 2004, he became
Assistant Vice President for European Life-Science Sales, and in
2005, Managing Director of Bruker Daltonik GmbH. He holds a Ph.D.
in drug discovery technology from The University of Bath, UK. Frank
Laukien, President and CEO of Bruker BioSciences, said: "I am very
pleased for Michael and Ian to assume additional management
responsibilities at Bruker Daltonics. Both of them have excellent
track records and I expect that in their expanded roles they will
contribute even more strongly to our corporate goals. By focusing
on customers, on technological and business innovation, and on
operational excellence we drive to continue our above
industry-standard revenue growth while reaching substantial
profitability." ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR) Bruker
BioSciences Corporation, headquartered in Billerica, Massachusetts,
is the publicly traded parent company of Bruker Daltonics Inc. and
Bruker AXS Inc. Bruker AXS is a leading developer and provider of
life science and advanced materials research tools based on x-ray
technology. Bruker Daltonics is a leading developer and provider of
innovative life science tools based on mass spectrometry. Bruker
Daltonics also offers a broad line of nuclear, biological and
chemical (NBC) detection products for defense and homeland
security. For more information, please visit
www.bruker-biosciences.com CAUTIONARY STATEMENT Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995.
Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results
to differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
reorganization strategies, integration risks, failure of
conditions, technological approaches, product development, market
acceptance, cost and pricing of the Company's products, exposure to
currency fluctuations, changes in governmental regulations, capital
spending and government funding policies, FDA and other regulatory
approvals to the extent applicable, competition, the intellectual
property of others, patent protection and litigation. These and
other factors are identified and described in more detail in our
filings with the SEC, including, without limitation, our respective
annual reports on Form 10-K for the year ended December 31, 2004,
our most recent quarterly reports on Form 10-Q, and our current
reports on Form 8-K. We disclaim any intent or obligation to update
these forward-looking statements.
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024